Skip to Main

Search

Results 651 to 660 of 938 for ""

Chemical modification of RNA could play key role in polycystic kidney disease: Newsroom - UT Southwestern, Dallas, Texas

https://www.utsouthwestern.edu/newsroom/articles/year-2021/chemical-modification-of-rna.html

A chemical modification of RNA that can be influenced by diet appears to play a key role in polycystic kidney disease, an inherited disorder that is the fourth leading cause of kidney failure in the U.S.

UT Southwestern nearly doubles lifespan of mice with brain cancer: Newsroom - UT Southwestern, Dallas, Texas

https://www.utsouthwestern.edu/newsroom/articles/year-2020/brain-cancer.html

UT Southwestern Simmons Cancer Center researchers have developed technology that is spawning a much better form of drug delivery for gene therapy and has achieved a 43 percent increase in the survival of mice with glioblastoma, one of the deadliest forms of human brain cancer.

Why the dose matters: Study shows that levels of drug in body correlate to ability to shrink tumors: Newsroom - UT Southwestern, Dallas, Texas

https://www.utsouthwestern.edu/newsroom/articles/year-2020/why-the-dose-matters.html

When used to manage infections, the drug itraconazole is generally given at a single, fixed dose to all patients.

UT Southwestern expands neurosurgical program to Texas Health Dallas: Newsroom - UT Southwestern, Dallas, Texas

https://www.utsouthwestern.edu/newsroom/articles/year-2020/neurosurgical-program.html

UT Southwestern Medical Center is expanding its neurological surgery program to Texas Health Presbyterian Hospital Dallas.

Inappropriate disclosure to vendor announced: Newsroom - UT Southwestern, Dallas, Texas

https://www.utsouthwestern.edu/newsroom/articles/year-2020/inappropriate-disclosure.html

UT Southwestern Medical Center has informed affected patients of an inappropriate disclosure of their email addresses through use of a third-party vendor.

UTSW study finds Hispanic people receive lower-quality thrombectomies than white people: Newsroom - UT Southwestern, Dallas, Texas

https://www.utsouthwestern.edu/newsroom/articles/year-2021/lower-quality-thrombectomies.html

A study by UT Southwestern neurology researchers found that Hispanic people have lower-quality outcomes than white people among ischemic stroke patients who receive endovascular thrombectomies. Racial disparities were not found between Black and white patients.

Researchers find immune component to rare neurodegenerative disease : Newsroom - UT Southwestern, Dallas, Texas

https://www.utsouthwestern.edu/newsroom/articles/year-2021/neurodegenerative-disease.html

UT Southwestern researchers have identified an immune protein tied to the rare neurodegenerative condition known as Niemann-Pick disease type C.

Study finds no danger of second COVID shot in those with allergic reactions to first dose: Newsroom - UT Southwestern, Dallas, Texas

https://www.utsouthwestern.edu/newsroom/articles/year-2021/second-covid-shot.html

People who had a potentially allergic reaction to their first messenger RNA COVID-19 vaccination can safely receive their second shot, according to a study of patients conducted at several medical centers, including UT Southwestern.

UT Southwestern scientists closing in on map of the mammalian immune system: Newsroom - UT Southwestern, Dallas, Texas

https://www.utsouthwestern.edu/newsroom/articles/year-2021/mammalian-immune-system.html

Using artificial intelligence, UT Southwestern scientists have identified thousands of genetic mutations likely to affect the immune system in mice. The work is part of one Nobel laureate’s quest to find virtually all such variations in mammals.

New NIH grant supports ongoing UTSW investigation of debilitating complications of blood clots in teens: Newsroom - UT Southwestern, Dallas, Texas

https://www.utsouthwestern.edu/newsroom/articles/year-2021/blood-clots-in-teens.html

UT Southwestern will lead a multicenter investigation into why children and young adults experience decreased physical activity and shortness of breath after experiencing blood clots, thanks to a four-year $2.97 million grant from the National Institutes of Health (NIH).